Is Provenge "Reasonable And Necessary"? CMS Analysis For Medicare Coverage Seeks To Find Out
This article was originally published in The Pink Sheet Daily
Executive Summary
The Centers for Medicare and Medicaid Services may consider setting formal parameters around Medicare coverage for Dendreon's ground-breaking prostate cancer vaccine Provenge next year.
You may also be interested in...
Kite’s Axi-Cel CAR-T: No Adcomm, No Problem
Next CAR-T in line at US FDA, Kite’s axicabtagene ciloleucel, looks headed toward an early approval with the agency confirming no panel will be scheduled, according to the firm. But the company and FDA may have benefited from an advisory committee review.
Prostate Cancer Market Snapshot: More Than Provenge
The launch of two drugs for metastatic prostate cancer this year – Dendreon Corp.'s Provenge (sipuleucel-T) and Sanofi-Aventis SA's Jevtana (cabazitaxel) – is shining a spotlight on an area of oncology that for many years was marked by a dearth of new treatment options.
Prostate Cancer Market Snapshot: More Than Provenge
The launch of two drugs for metastatic prostate cancer this year – Dendreon Corp.'s Provenge (sipuleucel-T) and Sanofi-Aventis SA's Jevtana (cabazitaxel) – is shining a spotlight on an area of oncology that for many years was marked by a dearth of new treatment options.